MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation |
|
|
| Recruiting | 3 | 1594 | Europe, Canada, US, RoW | Teclistamab, JNJ-64007957, Lenalidomide | Stichting European Myeloma Network, Janssen Pharmaceutica | Multiple Myeloma | 04/28 | 04/32 | | |
